Western States Scientific Safety Review Workgroup (WSSSRW) voted to recommend the use of the Moderna and Pfizer Bivalent Boosters, in agreement with the Advisory Committee on Immunization Practices (ACIP). Providers may administer the COVID-19 Bivalent Booster Vaccine to eligible individuals.
Eligibility
- Moderna Bivalent Booster is authorized and recommended for those 18 years and older.
- Pfizer Bivalent Booster is authorized and recommended for those 12 years and older.
- People cannot get a bivalent booster without first completing at least a primary series.
- Age-appropriate homologous and heterologous boosters allowed; there is no preference.
- The bivalent booster recommendation replaces previous booster recommendations for people 12 years and older.
Timing
- Administer at least 2 months after completion of the primary series or the most recent booster dose of an FDA approved or authorized monovalent (original) COVID-19 vaccine. Please refer to CDC clinical guidance for additional considerations on timing of the bivalent booster dose.
Current Procedural Terminology (CPT) codes for the COVID-19 Bivalent Boosters are:
- Moderna COVID-19, Bivalent Booster for 18+ Years
- 91313 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use
- 0134A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose
- Pfizer COVID-19, Bivalent Booster for 12+ Years
- 91312 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
- 0124A - Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose
Resources:
